Attached files
| file | filename |
|---|---|
| EX-99 - VIVOS INC | ex99-01022018_010108.htm |
| EX-1 - VIVOS INC | ex1-01022018_010107.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): December 28, 2017
Vivos Inc.
(Exact name of registrant as specified in its charter)
|
Delaware
|
00-53497
|
80-0138937
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
719 Jadwin Avenue
Richland, WA 99352
|
|
(Address of principal executive offices)
|
(509) 736-4000
(Registrant’s telephone number, including area
code)
Advanced Medical Isotope Corporation
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2) ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Changes in
Fiscal Year.
See
Item 8.01
Item 8.01
Other Information.
Effective December 28, 2017, Vivos Inc. (the
“Company”) amended its Certificate of Incorporation
to change the name of the Company from “Advanced Medical
Isotope Corporation” to “Vivos Inc.” (the
“Name
Change”). The Name Change
was approved by the Company’s Board of Directors, and was
adopted in accordance with Section 242 of the General Corporation
Law of the State of Delaware. A copy of the amendment to the
Company’s Certificate of Incorporation, as filed with the
Delaware Secretary of State, is attached hereto as Exhibit 3.1, and
is incorporated by reference herein.
The Name Change was approved by the Financial
Industry Regulation Authority (“FINRA”) on December 29, 2017, and became
effective with the OTC Market at the opening of trading on January
2, 2018 under the new symbol “RDGL.” The
Company’s new CUSIP number is 92858K105.
On
January 2, 2018, the Company issued a press release announcing the
Name Change and symbol change. A copy of the press release is
attached hereto as Exhibit 99.1.
Item 9.01
Financial
Statements and Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
Vivos Inc.
|
|
|
|
|
|
|
Date:
January 2, 2018
|
By:
|
/s/ L. Bruce Jolliff
|
|
|
|
L.
Bruce Jollif
Chief
Financial Officer
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
1.1
|
|
Certificate
of Amendment
|
|
99.1
|
|
Press
Release, dated January 2, 2018
|